Crexendo - CXDO Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Crexendo in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CXDO shares.
View CXDO analyst ratings or view top-rated stocks.

1 brokerages have issued twelve-month price targets for Crexendo's shares. Their CXDO share price forecasts range from $4.00 to $4.00. On average, they expect the company's stock price to reach $4.00 in the next year. This suggests a possible upside of 142.4% from the stock's current price.
View analysts price targets for CXDO or view top-rated stocks among Wall Street analysts.

Crexendo's stock was trading at $1.90 on January 1st, 2023. Since then, CXDO shares have decreased by 13.2% and is now trading at $1.65.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023.
View our CXDO earnings forecast.

Crexendo, Inc. (NASDAQ:CXDO) posted its quarterly earnings results on Monday, March, 21st. The company reported $0.02 EPS for the quarter, missing analysts' consensus estimates of $0.03 by $0.01. The business had revenue of $9 million for the quarter, compared to analyst estimates of $8.84 million. Crexendo had a negative net margin of 94.30% and a negative trailing twelve-month return on equity of 0.41%. During the same quarter last year, the business posted $0.37 earnings per share.

Crexendo declared a quarterly dividend on Tuesday, March 14th. Investors of record on Friday, March 31st will be given a dividend of $0.005 per share on Tuesday, April 11th. This represents a $0.02 dividend on an annualized basis and a yield of 1.21%. The ex-dividend date is Thursday, March 30th.
Read our dividend analysis for CXDO.

Crexendo (NASDAQ:CXDO) pays an annual dividend of $0.02 per share and currently has a dividend yield of 1.27%.
Read our dividend analysis for CXDO.

Based on aggregate information from My MarketBeat watchlists, some companies that other Crexendo investors own include Strongbridge Biopharma (SBBP), AcelRx Pharmaceuticals (ACRX), Aptinyx (APTX), Axcella Health (AXLA), Aytu BioPharma (AYTU), Calithera Biosciences (CALA), Cidara Therapeutics (CDTX), Catalyst Pharmaceuticals (CPRX), DURECT (DRRX) and Geron (GERN).

Crexendo trades on the NASDAQ under the ticker symbol "CXDO."

Crexendo's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Bard Associates Inc. (2.68%), Creative Planning (2.33%), Essex Investment Management Co. LLC (1.17%), Millennium Management LLC (0.19%), Renaissance Technologies LLC (0.11%) and Legato Capital Management LLC (0.10%). Insiders that own company stock include Anil K Puri, David Tzat-Kin Wang, Douglas Walter Gaylor, Jeffrey Parr Bash, Jon Brinton, Steven G Mihaylo, Steven G Mihaylo and Todd Andrew Goergen.
View institutional ownership trends.

Shares of CXDO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CXDO stock can currently be purchased for approximately $1.65.

Crexendo (NASDAQ:CXDO) has a market capitalization of $42.41 million and generates $37.55 million in revenue each year. The company earns $-35,410,000.00 in net income (profit) each year or ($1.53) on an earnings per share basis.

The company employs 121 workers across the globe.

Crexendo's mailing address is 1615 SOUTH 52ND STREET, TEMPE AZ, 85281. The official website for the company is www.crexendo.com. The company can be reached via phone at (602) 714-8500, via email at smihaylo@crexendo.com, or via fax at 302-674-5266.